Interestingly, epidemiological and experimental studies point to a potential role of the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) and BDNF in neuropsychiatric disorders, in particularly in depression [199]. Here, BDNF is linked to depressive disorder.